StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.33−0.04 (-9.78%)

Close on Nov 18, 2026Market cap $4.21MP/E –Yield –

Lantern Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Lantern Pharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$12.85M. For fiscal 2025 it was -$15.68M. The highest annual figure on record is -$2.13M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.68M–
FY2024Dec 31, 2024-$17.81M–
FY2023Dec 31, 2023-$14.35M–
FY2022Dec 31, 2022-$12.77M–
FY2021Dec 31, 2021-$10.59M–
FY2020Dec 31, 2020-$5.65M–
FY2019Dec 31, 2019-$2.13M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.34M–
Q2 FY2026Jun 30, 2026-$2.94M–
Q1 FY2026Mar 31, 2026-$3.77M–
Q4 FY2025Dec 31, 2025-$2.79M–
Q3 FY2025Sep 30, 2025-$4.57M–
Q2 FY2025Jun 30, 2025-$3.94M–
Q1 FY2025Mar 31, 2025-$4.38M–
Q4 FY2024Dec 31, 2024-$3.97M–
Q3 FY2024Sep 30, 2024-$5.58M–
Q2 FY2024Jun 30, 2024-$5.19M–
Q1 FY2024Mar 31, 2024-$3.07M–
Q4 FY2023Dec 31, 2023-$3.39M–
Q3 FY2023Sep 30, 2023-$3.61M–
Q2 FY2023Jun 30, 2023-$3.59M–
Q1 FY2023Mar 31, 2023-$3.76M–
Q4 FY2022Dec 31, 2022-$2.67M–
Q3 FY2022Sep 30, 2022-$4.04M–
Q2 FY2022Jun 30, 2022-$2.73M–
Q1 FY2022Mar 31, 2022-$3.33M–
Q4 FY2021Dec 31, 2021-$2.04M–
Q3 FY2021Sep 30, 2021-$4.68M–
Q2 FY2021Jun 30, 2021-$1.73M–
Q1 FY2021Mar 31, 2021-$2.14M–
Q4 FY2020Dec 31, 2020-$1.57M–
Q3 FY2020Sep 30, 2020-$2.89M–
Q2 FY2020Jun 30, 2020-$490.87K–
Q1 FY2020Mar 31, 2020-$703.05K–
Q4 FY2019Dec 31, 2019-$708.88K–
Q3 FY2019Sep 30, 2019-$549.93K–

More Lantern Pharma figures

See a number that looks wrong?